{"url_path":"/sec/jsprw/8-k/2026-06-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-063157-index.html","accession_number":"0001213900-26-063157","cik":"0001788028","ticker":"JSPR","issuer_name":"Jasper Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-063157-index.html","primary_entity_key":"0001788028","primary_entity_name":"Jasper Therapeutics, Inc."},"word_count":170,"has_tables":true,"body_markdown":"** **\n\n \n\n** **\n\n****\n\n \n\n \n\n** **\n\n**Item 7.01 Regulation FD Disclosure.**\n\n** **\n\nOn June 1, 2026, Jasper Therapeutics, Inc. issued a press release announcing\nthat, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic\nalternatives aimed at maximizing shareholder value. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on\nForm 8-K.\n\n \n\nIn accordance with General Instructions B.2 of Form 8-K, the information\nin this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 and Item 9.01 of Current\nReport on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended\n(the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be deemed incorporated by reference\nin any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference\nin such a filing."}